Please assess the completion status of the following clinical trial:

Trial Title: Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, 18 to 65 years of age who are diagnosed with HDV by PCR~* Chronic hepatitis D infection, genotype 1, documented by a positive anti-HDV Ab test at least of 6 months duration and detectable HDV RNA by PCR within 3 months to study entry~* Liver biopsy within the last two years (biopsy can be done at the Screening Visit)~* Positive viral load of \>100,000 copies/mL as measured by quantitative PCR~* Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality and a QT/QTc interval \<450 milliseconds - using Bazett's correction~* Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use one of the following acceptable birth control methods throughout the study:~  1. abstinence~ 2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) six months minimum~ 3. IUD in place for at least six months~ 4. barrier methods (condom or diaphragm) with spermicide~ 5. surgical sterilization of the partner (vasectomy for six months)~ 6. hormonal contraceptives for at least three months prior to the first dose of study drug~* Willing and able to comply with study procedures and provide written informed consent~Exclusion Criteria:~* Participation in a clinical trial with or use of any investigational agent within 30 days of Study Visit 1~* Patients co-infected with HIV~* Patients with screening tests positive for HCV, or anti-HIV Ab~* History of decompensated cirrhosis within the past year~* Active jaundice defined by total bilirubin \> 2.0 excluding Gilbert's disease~* INR ≥ 1.5~* Eating disorder or alcohol abuse within the past 2 years, excessive alcohol intake (\> 20 g per day for females (1.5 standard alcohol drinks) or \> 30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) (1.0 fluid oz (US) = 29.57 mL)~* Drug abuse within the last six months with the exception of cannabinoids and their derivatives~* Patients with absolute neutrophil count (ANC) \< 1500 cells/mm\^3; platelet count \< 100,000 cells/mm\^3; hemoglobin \< 12 g/dL for women and \< 13 g/dL for men; abnormal TSH,T4, or T3 or thyroid function not adequately controlled; or serum creatinine concentration ≥ 1.5 times upper limit of normal (ULN)~* History or clinical evidence of any of the following:~  1. variceal bleeding, ascites, hepatic encephalopathy, CTP score \> 6, decompensated liver disease or any other form of non-viral hepatitis~ 2. immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) requiring more than intermittent nonsteroidal anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids (inhaled asthma medications are allowed)~ 3. any malignancy within 3 years except for basal cell skin cancer~ 4. significant or unstable cardiac disease (e.g., angina, congestive heart failure, uncontrolled hypertension, history of arrhythmia)~ 5. chronic pulmonary disease (e.g., chronic obstructive pulmonary disease) associated with functional impairment~ 6. severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization 2~* Patients with a body mass index \> 30 kg/m\^2~* Concomitant drugs known to prolong the QT interval

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lonafarnib/ritonavir - I (Type: EXPERIMENTAL): lonafarnib 100 mg BID + ritonavir 100 mg QD
- lonafarnib/ritonavir - II (Type: EXPERIMENTAL): lonafarnib 100 mg BID + ritonavir 50 mg BID
- lonafarnib/ritonavir - III (Type: EXPERIMENTAL): lonafarnib 100 mg QD + ritonavir 100 mg QD
- lonafarnib/ritonavir - IV (Type: EXPERIMENTAL): lonafarnib 150 mg QD + ritonavir 100 mg QD
- lonafarnib/ritonavir/PEG IFN-a - V (Type: EXPERIMENTAL): lonafarnib 75 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
- lonafarnib/ritonavir - VI (Type: EXPERIMENTAL): lonafarnib 25 mg BID + ritonavir 100 mg BID
- lonafarnib/ritonavir - VII (Type: EXPERIMENTAL): lonafarnib 50 mg BID + ritonavir 100 mg BID
- lonafarnib/ritonavir/PEG IFN-a - VIII (Type: EXPERIMENTAL): lonafarnib 50 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
- lonafarnib/ritonavir/PEG IFN-a - IX (Type: EXPERIMENTAL): lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
- lonafarnib/ritonavir/PEG IFN-a - X (Type: EXPERIMENTAL): lonafarnib 50 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW

Based on this trial design, predict the completion outcome and termination type (if applicable).